Cat. No. 4482
Chemical Name: 2,6-Diamino-3,5-dithiocyanopyridine
Biological ActivityBroad spectrum, reversible DUB inhibitor. Exhibits limited activity against other proteases. Induces accumulation of polyubiquitinated proteins, but has no direct inhibitory effect on the proteasome. Cytotoxic in HEK293T and colorectal cancer cells. Stabilizes microtubule network in oligodendroglial cells.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Seiberlich et al (2012) The small molecule inhibitor PR-619 of deubiquitinating enzymes affects the microtubule network and causes protein aggregate formation in neural cells: implications for neurodegenerative diseases. Biochim.Biophys.Acta 1823 2057. PMID: 22565157.
Altun et al (2011) Activity-based chemical proteomics accelerates inhibitor development for deubiquitylating enzymes. Chem.Biol. 18 1401. PMID: 22118674.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses PR 619 from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: PR 619, supplier, PR619, inhibitors, DUBs, deubiquitinating, enzymes, deubiquitination, proteasome, inhibits, broad, spectrum, proteases, Tocris Bioscience, Deubiquitinating Enzyme Inhibitor products
Find multiple products by catalog number
New Products in this Area
High affinity angiotensin-converting enzyme (ACE) ligandTMI 1
Adam 17 (TACE) and MMP inhibitor; orally bioavailableRitonavir
HIV-1 and HIV-2 protease inhibitorAcetyl Pepstatin
High affinity aspartic protease inhibitor; inhibits HIV-1/2 proteinasesONO 6818
High affinity and selective human neutrophil elastase 1 (HNE1) inhibitor; orally active
Follow @Tocris on Twitter
Tocris is now actively tweeting. For regular updates on news, events and special offers, follow @Tocris on Twitter.